Bristol Myers Squibb has added a familiar face to an ongoing initiative to thank oncologists for the valuable time they ...

Sandoz has struck a deal with Samsung Bioepis to partner on up to five biosimilars, with the first being SB36, a copycat of ...

Much of President Donald Trump’s campaign promises to lower drug prices in the U.S. | According to a review by The New York ...

Since investment bank HSBC downgraded the stock of Eli Lilly from “hold” to “reduce” on Tuesday morning, the share price of ...

As interest in the cancer-fighting potential of radiopharmaceutical drugs continues to swell, companies have unleashed a ...

Johnson & Johnson and Protagonist Therapeutics are countering the swarm of injectable biologics that have long dominated the ...

Some three weeks into the U.S. and Israel’s war with Iran, the expanding conflict’s impact on energy prices and shipping in ...

Everyone’s favorite bracket challenge has returned. That’s right—it’s time once again for Fierce Pharma Marketing’s annual ...

Moderna CEO Stéphane Bancel’s total compensation remained remarkably stable last year at $19.9 million, even as the vaccines ...

Eli Lilly scored $408 million in U.S. sales of eczema treatment Ebglyss in its first full year on the market in 2025. | With ...

BioMarin will discontinue dosing and enrollment of its phase 2 trials for Voxzogo—currently approved in achondroplasia, a ...

It was only nine months ago that Idorsia announced a CEO change, tapping Srishti Gupt | Idorsia is gearing up for another CEO ...